Jeff Cranmer

Leads Biolabs' offering is the 16th biotech IPO on an East Asian exchange this year, 9 of which have been on the HKSE. 7 of those nine have come since mid-April. That compares with 11 biotech IPOs on NASDAQ in 2025.

Always knew Ozzy had a sweet tooth but thought it was for the leaf. h/t @BioBonanos

First clinical evidence spurs @sanofi takeout of @Medicxi best in class vax play Vicebio for $1.15B up front. via @BioBonanos: biocentury.com/article/656546

A leaked memo on @IAmBiotech strategy is energizing anti-vaxxers, writes @BioCentury's @steveusdin1. Document describes BIO's investment in pro-vaccine communications, plans to engage with conservatives in and outside the Trump administration biocentury.com/article/656351

hmm the possible next head of CDER. A marketing and management degree vs the acting head dr corrigan-coray

Amarin, Merck alum Karim Mikhail emerges as possible head of @US_FDA’s CDER, reports @BioCentury's @steveusdin1

🚨 NOLAN SMITH AUTO GIVEAWAY! 🚨 I’m giving away a Nolan Smith autographed rookie card following the launch of ThePhillySpecialShow.com! 👀 How to enter: 1) Follow @DiBonaNFL and @thePHIspecial 2) Reply to this tweet and tag a friend 3) Retweet this tweet Winner picked on 6/3!

The biopharma industry is racing to counter the Trump MFN threat: With White House demanding 85% across-the-board drug price cuts, the biopharma industry hopes to avoid catastrophic policies via alternative concessions, writes @BioCentury's @steveusdin1 biocentury.com/article/656077

Setback for Stealth raises questions about @US_FDA’s implementation of rare disease policies. The biotech’s regulatory odyssey in Barth syndrome exemplifies the problems Makary has vowed to fix. via @SteveUsdin1 in @BioCentury biocentury.com/article/656066

Looking for that special something to give your favorite @packers fan? Push here. #FlyEaglesFly

The biggest licensing deal yet for a China biotech asset -- @Pfizer taking rights to a 3SBio bispecific -- is also tied for 3rd largest biotech asset deal ever. The deal for a PD-(L)1 x VEGF has $PFE paying $1.25B u/f Here's @BioBonanos in @biocentury biocentury.com/article/655979

FDA misses PDUFA goal for Stealth’s Barth syndrome treatment It isn’t clear whether staffing cuts or loss of FDA champions have caused FDA to miss the PDUFA goal for an ultrarare disease therapy. biocentury.com/article/655776

Another missed deadline by RFK Jr. & Makary's @US_FDA -- this time for a treatment for a very rare disease: biocentury.com/article/655776

Krause, @llborio on turmoil @US_FDA: "Moving the goalposts like this has a chilling effect on the entire biotech community and reduces appetite to develop critically needed new drugs and biologics in areas beyond just vaccines, including immunotherapies and cancer treatments."

The leaked Trump administration 2026 HHS budget is sickening. If enacted, it will destroy American science. NIH budget slashed by 40%. The 15% overhead for universities baked into law. Ill-conceived reorganization of NIH institutes.

After 21 years at my dream job, I’m very sad to announce my early retirement from the National Institutes of Health. My life’s work has been to scientifically study how our food environment affects what we eat, and how what we eat affects our physiology. Lately, I’ve focused on…

Go Birds, @EmmittSmith22.

Makary filling key @US_FDA spots with Capitol Hill alum Grace Graham, Washington lawyer Lowell Zeta, @BioCentury's @steveusdin1 has learned. They'll join the agency's Office of the Commissioner

Shanghai ADC play Duality braved one of HK's worst downturns of past 20 yrs to stick its landing on the HKSE, offering hope to China biotechs that have been suffering through a multiyear financing drought. I took a closer look in today's @BioCentury : biocentury.com/article/655632

Small molecule #Alzheimer's tx hits Ph 3 setback at #ADPD2025, but study's PIs argue for a subgroup effect in early-stage patients and a new surrogate endpoint -- hippocampal volume. My @BioCentury colleague @SelinaMKoch reports on the data as presented in Vienna at @adpdnet